福安药业2024年度业绩网上说明会问答实录

Core Viewpoint - The company is actively engaging in investor relations and is committed to improving its market value through various measures, including performance enhancement and cash dividends [2][5][6]. Group 1: Company Performance and Financials - The company's consolidated revenue for 2024 was 23.91 billion yuan, with a cost of 11.25 billion yuan [3]. - The company plans to optimize its cost structure and enhance revenue by expanding its market for non-collective procurement products and leveraging its new intelligent manufacturing facilities [3][11]. - The company acknowledges the impact of industry policies on its performance and aims to stabilize its operational results [2][5]. Group 2: Market Value Management - The company is focused on enhancing investor relations and improving information disclosure quality as part of its market value management strategy [2][5][6]. - The company has no current plans for share buybacks but emphasizes its commitment to maintaining market value through operational improvements and cash dividends [4][12]. - The company understands investor concerns regarding stock price fluctuations and is dedicated to addressing these issues within legal and regulatory frameworks [6][10]. Group 3: Legal and Regulatory Matters - The company is currently involved in a lawsuit in the United States related to its investment, with no preliminary judgment yet [4][9]. - The company received an administrative regulatory decision from the China Securities Regulatory Commission, which it is addressing through legal means [6][10]. Group 4: Research and Development - The company is primarily focused on chemical pharmaceuticals and is currently conducting clinical trials for its partnered projects [5][11]. - The company has not disclosed any innovative drugs for sale, focusing instead on its extensive line of chemical generic drugs [8][11].